Skip to main content
Midas Edge

Mosaic ImmunoEngineering Inc.

For the period ended Dec 31, 2024. Filed Apr 15, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Apr 15, 2025

CPMVStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Balance Sheets

December 31, 2024December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents$115,019$156,178
Prepaid expenses and other current assets26,59223,355
Total current assets141,611179,533
Total assets$141,611$179,533
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable$134,865$118,478
Accrued compensation3,767,6523,184,911
Accrued consulting787,903787,903
Accrued expenses and other646,850641,763
Loan payable200,000–
Total current liabilities5,537,2704,733,055
Convertible notes, net1,392,5151,317,536
Total liabilities6,929,7856,050,591
Commitments and contingencies–
Stockholders’ deficit:
Preferred stock, $0.00001 par value; 5,000,000 shares authorized:–
Series A Convertible Voting Preferred Stock; 630,000 shares designated; no shares issued and outstanding––
Series B Convertible Voting Preferred Stock; 70,000 shares designated; 70,000 shares issued and outstanding11
Common stock, $0.00001 par value: 100,000,000 shares authorized: 7,242,137 shares issued and outstanding7272
Additional paid-in capital2,050,0732,045,206
Accumulated deficit(8,838,320)(7,916,337)
Total stockholders’ deficit(6,788,174)(5,871,058)
Total liabilities and stockholders’ deficit$141,611$179,533
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.